Eagle Ridge Investment Management Takes Position in Danaher Co. (NYSE:DHR)

Eagle Ridge Investment Management purchased a new stake in Danaher Co. (NYSE:DHR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 802 shares of the conglomerate’s stock, valued at approximately $223,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Fifth Third Wealth Advisors LLC boosted its position in shares of Danaher by 123.6% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 3,584 shares of the conglomerate’s stock valued at $895,000 after purchasing an additional 1,981 shares in the last quarter. Tsfg LLC boosted its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. Norway Savings Bank boosted its holdings in Danaher by 9.6% in the first quarter. Norway Savings Bank now owns 4,832 shares of the conglomerate’s stock worth $1,207,000 after acquiring an additional 425 shares in the last quarter. Norris Perne & French LLP MI boosted its holdings in Danaher by 2.1% in the first quarter. Norris Perne & French LLP MI now owns 78,772 shares of the conglomerate’s stock worth $19,671,000 after acquiring an additional 1,626 shares in the last quarter. Finally, Independence Bank of Kentucky boosted its holdings in Danaher by 72.1% in the first quarter. Independence Bank of Kentucky now owns 6,498 shares of the conglomerate’s stock worth $1,623,000 after acquiring an additional 2,723 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares of the company’s stock, valued at $11,501,145.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock valued at $8,400,897 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Danaher Stock Performance

Shares of DHR opened at $247.88 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $183.60 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 4.49 and a beta of 0.83. The stock has a 50 day moving average of $270.43 and a 200 day moving average of $260.43. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 earnings per share. Danaher’s revenue was up 3.1% on a year-over-year basis. As a group, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday. The Goldman Sachs Group increased their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners increased their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Royal Bank of Canada dropped their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Raymond James dropped their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.